| EPLBB03 | Cervical cancer screening outcomes among women living with HIV In Malawi | E-poster | Other non-communicable diseases |
| EPLBB02 | Chronic/latent viral infection prevalence and estimated all-cause mortality risk among women living with HIV and HIV-negative women participating in the British Columbia CARMA-CHIWOS Collaboration (BCC3) study: preliminary findings | E-poster | Opportunistic infections (excluding TB): Bacterial, non-TB mycobacterial, viral and parasitic infections |
| EPLBB01 | Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomized controlled trial | E-poster | Tuberculosis: Prevention, diagnosis, treatment |
| EPLBA08 | ILC3s in HIV-infected lymph nodes up-regulate inflammatory pathways linked to tissue fibrosis | E-poster | Innate immunity (including NK cells) |
| EPLBA07 | Host genetic variants regulates CCR5 expression on immune cells: a study in people living with HIV and healthy controls | E-poster | Correlates of HIV susceptibility, and progression versus control (biomarkers and genetics) |
| EPLBA06 | Deep down in the gut: analyzing the connection between epithelial cells and ART-induced inflammation | E-poster | HIV and co-morbidities |
| EPLBA05 | Translational potency of the antisense protein ORF in the proviral DNA context | E-poster | HIV biology (entry, replicative cycle, transcriptional expression and regulation) |
| EPLBA04 | CD8 depletion and N-803 plus anti-SIV Env RhmAbs in ART-suppressed rhesus macaques | E-poster | Strategies to control virologic rebound |
| EPLBA03 | Transcriptome analysis to identify the changes in microRNA expression profile and their targeted pathways in the cervicovaginal mucosa of HIV-infected women | E-poster | Mucosal immunity |
| EPLBA02 | Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T cell correlates of HIV-1 acquisition risk | E-poster | Cellular immunity; T cell vaccines |